CJC-1295 NO DAC + Ipamorelin (10 mg Blend) Dosage Protocol

Quickstart Highlights

This blend combines CJC-1295 (no DAC), a modified growth hormone-releasing hormone (GHRH) analog, with Ipamorelin, a selective growth hormone secretagogue (GHS)^[1]^[2]. CJC-1295 (no DAC) produces sustained, dose-dependent GH and IGF-1 increases^[1], while Ipamorelin selectively stimulates GH release without raising ACTH or cortisol^[3]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL total concentration (1.67 mg/mL each peptide).

Typical daily range: 100–300 mcg of each peptide once daily (gradual titration).

Easy measuring: At 3.33 mg/mL total, 1 unit = 0.01 mL ≈ 33.3 mcg of each peptide on a U-100 insulin syringe.

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL = ~3.33 mg/mL total)

Week	Daily Dose (mcg each)	Units (per injection) (mL)
Weeks 1–2	100 mcg each	3 units (0.03 mL)
Weeks 3–4	150 mcg each	4.5 units (0.045 mL)
Weeks 5–6	200 mcg each	6 units (0.06 mL)
Weeks 7–12	250–300 mcg each	7.5–9 units (0.075–0.09 mL)

Frequency: Inject once daily subcutaneously, typically before bed or upon waking^[4]. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid foaming.

Gently swirl/roll until dissolved (do not shake).

Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

Peptide Vials (CJC-1295 NO DAC + Ipamorelin, 10 mg blend each):

8 weeks ≈ 3 vials
12 weeks ≈ 4 vials
16 weeks ≈ 5 vials

Insulin Syringes (U-100, 30- or 50-unit preferred for low volumes):

Per week: 7 syringes (1/day)
8 weeks: 56 syringes
12 weeks: 84 syringes
16 weeks: 112 syringes

Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.

8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
16 weeks (5 vials): 15 mL → 2 × 10 mL bottles

Alcohol Swabs: One for the vial stopper + one for the injection site each day.

Per week: 14 swabs (2/day)
8 weeks: 112 swabs → recommend 2 × 100-count boxes
12 weeks: 168 swabs → recommend 2 × 100-count boxes
16 weeks: 224 swabs → recommend 3 × 100-count boxes

View Supplier

Protocol Overview

Concise summary of the once-daily regimen.

Goal: Support pulsatile GH release through synergistic GHRH + GHS stimulation^[4].

Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).

Dose Range: 100–300 mcg of each peptide daily with gradual titration.

Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL total) for accurate unit measurements.

Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Research Disclaimer